Cargando…

Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice

Endothelial dysfunction plays a central role in the pathogenesis of sepsis-mediated multiple organ failure. Several clinical and experimental studies have suggested that the glycocalyx is an early target of endothelial injury during an infection. Colivelin, a synthetic derivative of the mitochondria...

Descripción completa

Detalles Bibliográficos
Autores principales: Urban, Catherine, Hayes, Hannah V., Piraino, Giovanna, Wolfe, Vivian, Lahni, Patrick, O’Connor, Michael, Phares, Ciara, Zingarelli, Basilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478210/
https://www.ncbi.nlm.nih.gov/pubmed/36119052
http://dx.doi.org/10.3389/fimmu.2022.984298
_version_ 1784790518128967680
author Urban, Catherine
Hayes, Hannah V.
Piraino, Giovanna
Wolfe, Vivian
Lahni, Patrick
O’Connor, Michael
Phares, Ciara
Zingarelli, Basilia
author_facet Urban, Catherine
Hayes, Hannah V.
Piraino, Giovanna
Wolfe, Vivian
Lahni, Patrick
O’Connor, Michael
Phares, Ciara
Zingarelli, Basilia
author_sort Urban, Catherine
collection PubMed
description Endothelial dysfunction plays a central role in the pathogenesis of sepsis-mediated multiple organ failure. Several clinical and experimental studies have suggested that the glycocalyx is an early target of endothelial injury during an infection. Colivelin, a synthetic derivative of the mitochondrial peptide humanin, has displayed cytoprotective effects in oxidative conditions. In the current study, we aimed to determine the potential therapeutic effects of colivelin in endothelial dysfunction and outcomes of sepsis in vivo. Male C57BL/6 mice were subjected to a clinically relevant model of polymicrobial sepsis by cecal ligation and puncture (CLP) and were treated with vehicle or colivelin (100-200 µg/kg) intraperitoneally at 1 h after CLP. We observed that vehicle-treated mice had early elevation of plasma levels of the adhesion molecules ICAM-1 and P-selectin, the angiogenetic factor endoglin and the glycocalyx syndecan-1 at 6 h after CLP when compared to control mice, while levels of angiopoietin-2, a mediator of microvascular disintegration, and the proprotein convertase subtilisin/kexin type 9, an enzyme implicated in clearance of endotoxins, raised at 18 h after CLP. The early elevation of these endothelial and glycocalyx damage biomarkers coincided with lung histological injury and neutrophil inflammation in lung, liver, and kidneys. At transmission electron microscopy analysis, thoracic aortas of septic mice showed increased glycocalyx breakdown and shedding, and damaged mitochondria in endothelial and smooth muscle cells. Treatment with colivelin ameliorated lung architecture, reduced organ neutrophil infiltration, and attenuated plasma levels of syndecan-1, tumor necrosis factor-α, macrophage inflammatory protein-1α and interleukin-10. These therapeutic effects of colivelin were associated with amelioration of glycocalyx density and mitochondrial structure in the aorta. At molecular analysis, colivelin treatment was associated with inhibition of the signal transducer and activator of transcription 3 and activation of the AMP-activated protein kinase in the aorta and lung. In long-term outcomes studies up to 7 days, co-treatment of colivelin with antimicrobial agents significantly reduced the disease severity score when compared to treatment with antibiotics alone. In conclusion, our data support that damage of the glycocalyx is an early pathogenetic event during sepsis and that colivelin may have therapeutic potential for the treatment of sepsis-associated endothelial dysfunction.
format Online
Article
Text
id pubmed-9478210
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94782102022-09-17 Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice Urban, Catherine Hayes, Hannah V. Piraino, Giovanna Wolfe, Vivian Lahni, Patrick O’Connor, Michael Phares, Ciara Zingarelli, Basilia Front Immunol Immunology Endothelial dysfunction plays a central role in the pathogenesis of sepsis-mediated multiple organ failure. Several clinical and experimental studies have suggested that the glycocalyx is an early target of endothelial injury during an infection. Colivelin, a synthetic derivative of the mitochondrial peptide humanin, has displayed cytoprotective effects in oxidative conditions. In the current study, we aimed to determine the potential therapeutic effects of colivelin in endothelial dysfunction and outcomes of sepsis in vivo. Male C57BL/6 mice were subjected to a clinically relevant model of polymicrobial sepsis by cecal ligation and puncture (CLP) and were treated with vehicle or colivelin (100-200 µg/kg) intraperitoneally at 1 h after CLP. We observed that vehicle-treated mice had early elevation of plasma levels of the adhesion molecules ICAM-1 and P-selectin, the angiogenetic factor endoglin and the glycocalyx syndecan-1 at 6 h after CLP when compared to control mice, while levels of angiopoietin-2, a mediator of microvascular disintegration, and the proprotein convertase subtilisin/kexin type 9, an enzyme implicated in clearance of endotoxins, raised at 18 h after CLP. The early elevation of these endothelial and glycocalyx damage biomarkers coincided with lung histological injury and neutrophil inflammation in lung, liver, and kidneys. At transmission electron microscopy analysis, thoracic aortas of septic mice showed increased glycocalyx breakdown and shedding, and damaged mitochondria in endothelial and smooth muscle cells. Treatment with colivelin ameliorated lung architecture, reduced organ neutrophil infiltration, and attenuated plasma levels of syndecan-1, tumor necrosis factor-α, macrophage inflammatory protein-1α and interleukin-10. These therapeutic effects of colivelin were associated with amelioration of glycocalyx density and mitochondrial structure in the aorta. At molecular analysis, colivelin treatment was associated with inhibition of the signal transducer and activator of transcription 3 and activation of the AMP-activated protein kinase in the aorta and lung. In long-term outcomes studies up to 7 days, co-treatment of colivelin with antimicrobial agents significantly reduced the disease severity score when compared to treatment with antibiotics alone. In conclusion, our data support that damage of the glycocalyx is an early pathogenetic event during sepsis and that colivelin may have therapeutic potential for the treatment of sepsis-associated endothelial dysfunction. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9478210/ /pubmed/36119052 http://dx.doi.org/10.3389/fimmu.2022.984298 Text en Copyright © 2022 Urban, Hayes, Piraino, Wolfe, Lahni, O’Connor, Phares and Zingarelli https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Urban, Catherine
Hayes, Hannah V.
Piraino, Giovanna
Wolfe, Vivian
Lahni, Patrick
O’Connor, Michael
Phares, Ciara
Zingarelli, Basilia
Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
title Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
title_full Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
title_fullStr Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
title_full_unstemmed Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
title_short Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
title_sort colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478210/
https://www.ncbi.nlm.nih.gov/pubmed/36119052
http://dx.doi.org/10.3389/fimmu.2022.984298
work_keys_str_mv AT urbancatherine colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT hayeshannahv colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT pirainogiovanna colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT wolfevivian colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT lahnipatrick colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT oconnormichael colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT pharesciara colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice
AT zingarellibasilia colivelinasyntheticderivativeofhumaninamelioratesendothelialinjuryandglycocalyxsheddingaftersepsisinmice